The intracellular uptake of dasatinib was not significantly reduced when the dual OCT1 and OCT3 inhibitor prazosin was added to mononuclear cells of chronic phase CML patients, indicating that it is not transported by these proteins [124]. This evidence concerns the gene SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive.